Aridis Pharmaceuticals Stock Net Income
| ARDS Stock | USD 0.0002 0.0001 33.33% |
As of the 30th of January, Aridis Pharmaceuticals shows the Downside Deviation of 89.61, risk adjusted performance of 0.2531, and Mean Deviation of 208.65. Aridis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aridis Pharmaceuticals information ratio, as well as the relationship between the potential upside and kurtosis to decide if Aridis Pharmaceuticals is priced correctly, providing market reflects its regular price of 2.0E-4 per share. As Aridis Pharmaceuticals appears to be a penny stock we also recommend to validate its total risk alpha numbers.
Aridis Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aridis Pharmaceuticals' valuation are provided below:Aridis Pharmaceuticals does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Aridis |
Aridis Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aridis Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aridis Pharmaceuticals.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Aridis Pharmaceuticals on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Aridis Pharmaceuticals or generate 0.0% return on investment in Aridis Pharmaceuticals over 90 days. Aridis Pharmaceuticals is related to or competes with HST Global. Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of target... More
Aridis Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aridis Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aridis Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 89.61 | |||
| Information Ratio | 0.3347 | |||
| Maximum Drawdown | 1141.3 | |||
| Value At Risk | (90.48) | |||
| Potential Upside | 1000.0 |
Aridis Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aridis Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aridis Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Aridis Pharmaceuticals historical prices to predict the future Aridis Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.2531 | |||
| Jensen Alpha | 105.08 | |||
| Total Risk Alpha | 83.09 | |||
| Sortino Ratio | 1.17 | |||
| Treynor Ratio | 23.27 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aridis Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aridis Pharmaceuticals January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.2531 | |||
| Market Risk Adjusted Performance | 23.28 | |||
| Mean Deviation | 208.65 | |||
| Semi Deviation | 36.74 | |||
| Downside Deviation | 89.61 | |||
| Coefficient Of Variation | 298.57 | |||
| Standard Deviation | 314.45 | |||
| Variance | 98881.72 | |||
| Information Ratio | 0.3347 | |||
| Jensen Alpha | 105.08 | |||
| Total Risk Alpha | 83.09 | |||
| Sortino Ratio | 1.17 | |||
| Treynor Ratio | 23.27 | |||
| Maximum Drawdown | 1141.3 | |||
| Value At Risk | (90.48) | |||
| Potential Upside | 1000.0 | |||
| Downside Variance | 8030.47 | |||
| Semi Variance | 1350.04 | |||
| Expected Short fall | (715.82) | |||
| Skewness | 2.29 | |||
| Kurtosis | 3.73 |
Aridis Pharmaceuticals Backtested Returns
Aridis Pharmaceuticals is out of control given 3 months investment horizon. Aridis Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.35, which signifies that the company had a 0.35 % return per unit of risk over the last 3 months. We were able to break down twenty-seven different technical indicators, which can help you to evaluate if expected returns of 110.56% are justified by taking the suggested risk. Use Aridis Pharmaceuticals Mean Deviation of 208.65, risk adjusted performance of 0.2531, and Downside Deviation of 89.61 to evaluate company specific risk that cannot be diversified away. Aridis Pharmaceuticals holds a performance score of 27 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 4.53, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Aridis Pharmaceuticals will likely underperform. Use Aridis Pharmaceuticals total risk alpha and the relationship between the potential upside and period momentum indicator , to analyze future returns on Aridis Pharmaceuticals.
Auto-correlation | 0.03 |
Virtually no predictability
Aridis Pharmaceuticals has virtually no predictability. Overlapping area represents the amount of predictability between Aridis Pharmaceuticals time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aridis Pharmaceuticals price movement. The serial correlation of 0.03 indicates that only 3.0% of current Aridis Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.03 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Aridis Pharmaceuticals reported net income of (30.37 Million). This is 108.9% lower than that of the Biotechnology sector and 143.36% lower than that of the Health Care industry. The net income for all United States stocks is 105.32% higher than that of the company.
Aridis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aridis Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics of similar companies.Aridis Pharmaceuticals is currently under evaluation in net income category among its peers.
Aridis Fundamentals
| Return On Asset | -1.08 | |||
| Operating Margin | (9.58) % | |||
| Current Valuation | 12.11 M | |||
| Shares Outstanding | 36.21 M | |||
| Shares Owned By Insiders | 31.53 % | |||
| Shares Owned By Institutions | 11.60 % | |||
| Number Of Shares Shorted | 2 M | |||
| Price To Earning | (1.41) X | |||
| Price To Book | 5.40 X | |||
| Price To Sales | 7.33 X | |||
| Gross Profit | (22.61 M) | |||
| EBITDA | (29.51 M) | |||
| Net Income | (30.37 M) | |||
| Cash And Equivalents | 6.32 M | |||
| Cash Per Share | 0.36 X | |||
| Total Debt | 6.13 M | |||
| Debt To Equity | (0.18) % | |||
| Current Ratio | 0.41 X | |||
| Book Value Per Share | (0.77) X | |||
| Cash Flow From Operations | (29.13 M) | |||
| Short Ratio | 0.22 X | |||
| Earnings Per Share | (1.15) X | |||
| Price To Earnings To Growth | (0.02) X | |||
| Target Price | 10.0 | |||
| Number Of Employees | 37 | |||
| Beta | 0.78 | |||
| Market Capitalization | 13.24 M | |||
| Total Asset | 14.7 M | |||
| Retained Earnings | (195.67 M) | |||
| Working Capital | (25.27 M) | |||
| Current Asset | 27.39 M | |||
| Current Liabilities | 3.06 M | |||
| Z Score | -26.03 | |||
| Net Asset | 14.7 M |
About Aridis Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aridis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aridis Pink Sheet Analysis
When running Aridis Pharmaceuticals' price analysis, check to measure Aridis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aridis Pharmaceuticals is operating at the current time. Most of Aridis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aridis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aridis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aridis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.